Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.56 |
| ▸ | JAK1 | P23458 | 3/20 | 0.56 |
| ▸ | TYK2 | P29597 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 10/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486356 | 0.94 | TYK2 (0.61) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL26773164 | 0.94 | TYK2 (0.61) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL26773643 | 0.91 | JAK2 (0.50) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL26773320 | 0.91 | MAPT (0.47) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL26773315 | 0.91 | TYK2 (0.45) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL26777206 | 0.90 | HPGD (0.47) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL26773322 | 0.90 | HPGD (0.47) | JAK2JAK1TYK2JAK3HPGD | |
| SCHEMBL26773585 | 0.90 | JAK2 (0.51) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL26779368 | 0.89 | JAK2 (0.48) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL26773658 | 0.89 | HPGD (0.44) | JAK2JAK1TYK2JAK3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192464-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Origenis GmbH (DE) | 2023-06-14 | — | — | EP | claimed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | JAK2 89/4885JAK1 34/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.